A Phase 4 interventional study of Fluticasone propionate and Fluticasone propionate/salmeterol in Asthma, sponsored by GlaxoSmithKline. Completed at 65 sites in 12 countries. Open to participants aged 4 Years to 11 Years. Per ClinicalTrials.gov, last updated 2018-05-29.
Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 147 studies testing fluticasone in Asthma — 1 open to participants now, 4 under way, 2 of them phase 3. Fluticasone · Asthma.
Among the 147 studies testing fluticasone in Asthma, this one is the 28th largest by enrollment of the 146 interventional ones that give a count, is one of 9 that started in 2005, is one of 52 in phase 4, and was the 18th registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →1 of the 147 studies testing fluticasone in Asthma is open now, in 1 country. Recruiting first, the newest first:
University of Wisconsin, Madison · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Fluticasone: first FDA approval 1990 (CUTIVATE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.
This study: 4 Years to 11 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
147 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 9 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 506 is above the median of 79 across 3,346 interventional studies indexed under Asthma.
Median enrollment 100 across the 146 interventional studies. Of the 130 that completed or were terminated, 68 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
107 of 147 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,652 studies on the registry; 118 are open to participants now.
Of its 267 completed or terminated interventional studies of FDA-regulated products, 241 (90%) have results posted.
262 studies in Asthma by GlaxoSmithKline: 7 open now, 12 under way, 7 of them phase 3. Of 240 finished, 132 (55%) have results posted.
Among the 262 studies in Asthma by GlaxoSmithKline, this one is the 41st largest by enrollment of the 238 interventional ones that give a count, is one of 17 that started in 2005, is one of 53 in phase 4, and was the 22nd registered.
GlaxoSmithKline’s Asthma studies by the year they started, since 1999.
2 of the studies testing fluticasone in Asthma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05757102Phase 3GlaxoSmithKlineA Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma | 2027-01-26 |
| NCT07664527University of Wisconsin, MadisonNovel Method for Removal of Orally Deposited Inhaled Fluticasone Propionate | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 147 studies testing fluticasone in Asthma, from their registry updates:
Among GlaxoSmithKline’s 262 in Asthma:
This tab as a report to print or save as PDF → With an account.
This study will compare two treatment strategies (doubling the dose of inhaled steroids or adding a long acting beta2 agonist to the inhaled steroid at the same dose) in children not controlled by inhaled steroid alone at medium dose. The fixed combination SERETIDE 100/50 one inhalation twice daily will be compared to FLIXOTIDE 100 two inhalations twice daily.
A multicentre, randomised, double-blind, double dummy, parallel group study to compare the salmeterol/fluticasone propionate combination (SERETIDE™) at a dose of 50/100mcg twice daily and fluticasone propionate (FLIXOTIDE™) at a dose of 200mcg twice daily, both delivered via a dry powder inhaler (DISKUS™) for 12 weeks in asthma in children aged 4-11 years not controlled by inhaled corticosteroids alone at medium dose
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
At the end of the run-in period (Visit 2), subjects must still meet the criteria for entry into the run-in period and also have:
Exclusion criteria:
Subjects will be excluded from participating in the treatment period of the study if the following occurred during the run-in period:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Fluticasone propionate (FLIXOTIDE™) at a dose of 200μg twice daily
Drug: Fluticasone propionate
Salmeterol/fluticasone propionate combination (SERETIDE™) at a dose of 50/100μg twice daily
Drug: Fluticasone propionate/salmeterol
200μg twice daily
Drug pages: Fluticasone · Salmeterol Xinafoate
50/100μg twice daily
Also known as: Fluticasone propionate
Mean Change From Baseline in Morning Peak Expiratory Flow (PEF) Over 12 Weeks in Intent-to-treat (ITT) Population
PEF is the maximum flow generated during expiration, as measured with a peak flow meter and recorded in electronic diary record card (eDRC), performed with maximal force and started after a full inspiration. The mean morning PEF measurement was constructed by calculating a simple mean for each participant over the interval Weeks 1 to 12. All PEF measurements were converted to the Wright/McKerow peak flow meter scale for the purposes of analyses. The change from Baseline is then calculated by subtracting the Baseline PEF values from the individual on-treatment values. Baseline was calculated as the mean of the values recorded on the seven days preceding randomization. The analysis was done using analysis of covariance (ANCOVA) adjusted for baseline PEF, country amalgamation, age, sex and treatment.
Time frame: Baseline; Week 1 up to Week 12
Mean Change From Baseline in Morning PEF Over 12 Weeks in Per Protocol (PP) Population
PEF is the maximum flow generated during expiration, as measured with a peak flow meter and recorded in eDRC, performed with maximal force and started after a full inspiration. The mean morning PEF measurement was constructed by calculating a simple mean for each participant over the interval Weeks 1 to 12. All PEF measurements were converted to the Wright/McKerow peak flow meter scale for the purposes of analyses. The change from Baseline is then calculated by subtracting the Baseline PEF values from the individual on-treatment values. Baseline was calculated as the mean of the values recorded on the seven days preceding randomization. The analysis was done using ANCOVA adjusted for baseline PEF, country amalgamation, age, sex and treatment.
Time frame: Baseline; Week 1 up to Week 12
Number of Participants Who Achieved 'Totally Controlled' (TC) Asthma
TC asthma is defined as no daily symptoms, no night-time wakening due to asthma, no exacerbations, no rescue salbutamol/albuterol use, no emergency visits, \>=80% predicted morning PEF, and no treatment related adverse events enforcing a change in asthma therapy over 7 consecutive days. Number of participants/group who achieved the status of at least TC during the last 8 weeks (wks) of treatment was analyzed using logistic regression, including covariates for sex, age, treatment group, country amalgamation and baseline pre-bronchodilator Forced Expiratory Volume in one second (FEV1). Asthma control was assessed each week for the last 8 wks of treatment period. Each week was classified as 'TC', 'Well Controlled' (WC), 'Not Controlled' or 'Unevaluable'. A participant was considered to have TC asthma if they achieved 4/4, 5/5, 6/6, 6/7, 7/8 or 8/8 wks that were TC. 'Unevaluable' classification included participants with less than 4 wks of data during the assessment period.
Time frame: Week 5 up to Week 12
Number of Participants Who Achieved WC Asthma
WC asthma is defined as two or more of symptom score \>1 only allowed on \<=2 days/week, rescue salbutamol/albuterol use on \<=2 days/week and up to a maximum of 4 times per week, \>=80% predicted morning PEF daily assessed for 7 consecutive days and all the following criteria: no night-time awakening due to asthma, no exacerbations, no emergency visits, no treatment related adverse events enforcing a change in any asthma therapy. Number of participants/group who achieved the status of at least WC during the last 8 wks of treatment was analyzed using logistic regression, including covariates for sex, age, treatment group, country amalgamation and baseline prebronchodilator FEV1. Each week was classified as 'WC', 'Not Controlled' or 'Unevaluable'. A participant was considered to have WC asthma if they achieved 4/4, 5/5, 6/6, 6/7, 7/8 or 8/8 wks that were WC. 'Unevaluable' classification included participants with less than 4 wks of data during the assessment period.
Time frame: Week 5 up to Week 12
The study was conducted at 46 sites in 12 countries: Belgium (4), Denmark (1), France (8), Italy (3), Latvia (3), Lithuania (3), the Netherlands (6), Norway (1), Poland (4), Russian Federation (9), Spain (3) and Sweden (1) from 18 November 2005 to 26 October 2006.
| Milestone | FP 200 mcg BD | Salmeterol/Fluticasone Propionate (SFC) 50/100 mcg BD |
|---|---|---|
| Started | 153 | 150 |
| Completed | 147 | 147 |
| Not completed | 6 | 3 |
| Withdrew: Protocol violation | 1 | 2 |
| Withdrew: Exacerbation | 1 | 0 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Physician decision | 2 | 0 |
| Withdrew: Withdrawal by subject | 1 | 1 |
PEF is the maximum flow generated during expiration, as measured with a peak flow meter and recorded in electronic diary record card (eDRC), performed with maximal force and started after a full inspiration. The mean morning PEF measurement was constructed by calculating a simple mean for each participant over the interval Weeks 1 to 12. All PEF measurements were converted to the Wright/McKerow peak flow meter scale for the purposes of analyses. The change from Baseline is then calculated by subtracting the Baseline PEF values from the individual on-treatment values. Baseline was calculated as the mean of the values recorded on the seven days preceding randomization. The analysis was done using analysis of covariance (ANCOVA) adjusted for baseline PEF, country amalgamation, age, sex and treatment.
| Liters/Minute (L/min) | FP 200 mcg BD | SFC 50/100 mcg BD |
|---|---|---|
| Mean Change From Baseline in Morning Peak Expiratory Flow (PEF) Over 12 Weeks in Intent-to-treat (ITT) Population | 19.3 ± 2.12 | 26.9 ± 2.13 |
PEF is the maximum flow generated during expiration, as measured with a peak flow meter and recorded in eDRC, performed with maximal force and started after a full inspiration. The mean morning PEF measurement was constructed by calculating a simple mean for each participant over the interval Weeks 1 to 12. All PEF measurements were converted to the Wright/McKerow peak flow meter scale for the purposes of analyses. The change from Baseline is then calculated by subtracting the Baseline PEF values from the individual on-treatment values. Baseline was calculated as the mean of the values recorded on the seven days preceding randomization. The analysis was done using ANCOVA adjusted for baseline PEF, country amalgamation, age, sex and treatment.
| L/min | FP 200 mcg BD | SFC 50/100 mcg BD |
|---|---|---|
| Mean Change From Baseline in Morning PEF Over 12 Weeks in Per Protocol (PP) Population | 18.4 ± 2.14 | 27.7 ± 2.21 |
TC asthma is defined as no daily symptoms, no night-time wakening due to asthma, no exacerbations, no rescue salbutamol/albuterol use, no emergency visits, \>=80% predicted morning PEF, and no treatment related adverse events enforcing a change in asthma therapy over 7 consecutive days. Number of participants/group who achieved the status of at least TC during the last 8 weeks (wks) of treatment was analyzed using logistic regression, including covariates for sex, age, treatment group, country amalgamation and baseline pre-bronchodilator Forced Expiratory Volume in one second (FEV1). Asthma control was assessed each week for the last 8 wks of treatment period. Each week was classified as 'TC', 'Well Controlled' (WC), 'Not Controlled' or 'Unevaluable'. A participant was considered to have TC asthma if they achieved 4/4, 5/5, 6/6, 6/7, 7/8 or 8/8 wks that were TC. 'Unevaluable' classification included participants with less than 4 wks of data during the assessment period.
| Participants | FP 200 mcg BD | SFC 50/100 mcg BD |
|---|---|---|
| Number of Participants Who Achieved 'Totally Controlled' (TC) Asthma | 23 | 28 |
WC asthma is defined as two or more of symptom score \>1 only allowed on \<=2 days/week, rescue salbutamol/albuterol use on \<=2 days/week and up to a maximum of 4 times per week, \>=80% predicted morning PEF daily assessed for 7 consecutive days and all the following criteria: no night-time awakening due to asthma, no exacerbations, no emergency visits, no treatment related adverse events enforcing a change in any asthma therapy. Number of participants/group who achieved the status of at least WC during the last 8 wks of treatment was analyzed using logistic regression, including covariates for sex, age, treatment group, country amalgamation and baseline prebronchodilator FEV1. Each week was classified as 'WC', 'Not Controlled' or 'Unevaluable'. A participant was considered to have WC asthma if they achieved 4/4, 5/5, 6/6, 6/7, 7/8 or 8/8 wks that were WC. 'Unevaluable' classification included participants with less than 4 wks of data during the assessment period.
| Participants | FP 200 mcg BD | SFC 50/100 mcg BD |
|---|---|---|
| Number of Participants Who Achieved WC Asthma | 61 | 65 |
Collected over Serious adverse events and non-serious adverse events were collected from the first day of treatment until the last day of treatment (up to 12 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| FP 200 mcg BD | — | 3/153 (2%) | 61/153 (39.9%) |
| SFC 50/100 mcg BD | — | 3/150 (2%) | 55/150 (36.7%) |
| Event | FP 200 mcg BD | SFC 50/100 mcg BD |
|---|---|---|
| ConcussionInjury, poisoning and procedural complications | 0/153 | 1/150 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 1/153 | 1/150 |
| LaryngotracheitisInfections and infestations | 0/153 | 1/150 |
| GastritisGastrointestinal disorders | 1/153 | 0/150 |
| Wound infectionInfections and infestations | 1/153 | 0/150 |
| Event | FP 200 mcg BD | SFC 50/100 mcg BD |
|---|---|---|
| HeadacheNervous system disorders | 23/153 | 27/150 |
| NasopharyngitisInfections and infestations | 19/153 | 14/150 |
| RhinitisInfections and infestations | 10/153 | 12/150 |
| CoughRespiratory, thoracic and mediastinal disorders | 10/153 | 7/150 |
| Rhinitis allergicRespiratory, thoracic and mediastinal disorders | 10/153 | 6/150 |
| Abdominal painGastrointestinal disorders | 6/153 | 8/150 |
| Age, Continuous(Years) | FP 200 mcg BD | SFC 50/100 mcg BD | Total |
|---|---|---|---|
| Mean | 8.0 ± 2.01 | 8.1 ± 2.00 | 8.0 ± 2.00 |
| Sex: Female, Male(Participants) | FP 200 mcg BD | SFC 50/100 mcg BD | Total |
|---|---|---|---|
| Female | 55 | 53 | 108 |
| Male | 98 | 97 | 195 |
| Race/Ethnicity, Customized(Participants) | FP 200 mcg BD | SFC 50/100 mcg BD | Total |
|---|---|---|---|
| African American/African Heritage | 3 | 2 | 5 |
| White - Arabic/North African Heritage | 4 | 4 | 8 |
| White - White/Caucasian/European Heritage | 146 | 144 | 290 |
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
Ran from Nov 2005 to primary completion in Oct 2006, 11 months.
Results were first posted in Apr 2017, 10 years 5 months after primary completion.
Of 66 industry-sponsored phase 4 interventional studies under Asthma, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 33. This study's 11 months is below that.
Counting every sponsor, half of 156 studies reached it within 24 months; a quarter within 11 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Fluticasone · Salmeterol Xinafoate